NanoViricides, Inc. (NYSE American: NNVC) announced it is awaiting regulatory approval to begin a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of Bundibugyo ebolavirus in the Democratic Republic of the Congo. The company has submitted an application to the local regulatory agency and secured financing to support the study, which aims to evaluate the oral antiviral in response to an ongoing Ebola outbreak where no approved treatment or vaccine currently exists for the Bundibugyo strain.
According to the company, NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical testing. NanoViricides believes its broad-spectrum antiviral mechanism could offer advantages over infusion-based therapies in resource-limited outbreak settings. The company noted that sufficient quantities of the drug are already in the DRC to support the planned study, pending regulatory approval.
The development is significant because the Bundibugyo ebolavirus strain has limited treatment options. Current therapies for other Ebola strains require intravenous administration, which can be challenging in remote areas with limited healthcare infrastructure. An oral formulation like NV-387 could potentially be distributed more easily and administered without specialized medical personnel, improving access to treatment during outbreaks.
NanoViricides' lead drug candidate, NV-387, is also being developed for other viral infections, including RSV, COVID-19, influenza, and MPOX. The company's nanoviricide technology uses specially designed nanomaterials to target viruses, and NV-387 is designed to work against a broad spectrum of viruses. The company holds exclusive licenses for this technology for several viral diseases.
The ongoing Ebola outbreak in the DRC underscores the need for effective treatments. The World Health Organization has reported cases of Bundibugyo ebolavirus, which has a lower fatality rate than the Zaire strain but still poses a public health threat. If approved, the Phase II trial would evaluate the safety and efficacy of NV-387 in infected patients.
Investors can find more information about NanoViricides and its pipeline on the company's website and newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/t1kLC.
